ImmuCell Corporation (ICCC) Stock Price & Analysis
ImmuCell Corporation (ICCC) closed at USD 10.25 on Friday, October 23, 2026, down 1.35% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 10.39; the Oct 23, 2026 session ranged USD 10.2–10.37 on volume of 11,223 shares. Market capitalization is $93.09M, with a 52-week range of USD 4.52–12.1 (NCM). Source: Nexqual, retrieved October 24, 2026 at 01:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ICCC.md
Key facts (ICCC)
- Last four reported quarters (through Jun 30, 2026): revenue $30.7M, net income $787K (2.6% margin), free cash flow $4.2M (SEC filings).
- Valuation: P/E 118.2x, EV/EBITDA 14.7x, net cash $557K.
- Earnings quality: non-operating income -$3.0M vs operating income $3.9M over the last four quarters; P/E excluding non-operating income ≈26.1x (estimate: non-operating income taxed at the company's 7.8% effective rate).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $76K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: None.
- Total return with dividends: 1Y +71.7% vs S&P 500 +14.0%; 5Y +16.5% vs S&P 500 +76.9%.
- Next earnings: 2026-11-12, EPS estimate USD —, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ICCC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $19.2M | $18.6M | $17.5M | $26.5M | $27.6M | $30.7M |
| Gross profit | $8.7M | $7.6M | $3.9M | $7.9M | $11.4M | — |
| Operating income | $257K | -$2.3M | -$5.7M | -$1.6M | $1.6M | $3.9M |
| Net income | -$78K | -$2.5M | -$5.8M | -$2.2M | -$1.0M | $787K |
| EPS (diluted) | -$0.01 | -$0.32 | -$0.75 | -$0.26 | -$0.12 | — |
| Free cash flow | -$1.7M | -$5.5M | -$6.6M | -$108K | $1.2M | $4.2M |
| Gross margin | 45.0% | 41.2% | 22.1% | 30.0% | 41.4% | — |
| Operating margin | 1.3% | -12.4% | -32.9% | -6.2% | 6.0% | 12.6% |
| Net margin | -0.4% | -13.4% | -33.1% | -8.1% | -3.8% | 2.6% |
| Revenue growth | +25.4% | -3.5% | -5.9% | +51.6% | +4.3% | — |
| Cash + short-term investments | $10.2M | — | $979K | $3.8M | $3.8M | — |
| Total debt | $812K | $19.1M | $21.0M | $10.5M | $9.1M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ICCC)
P/E 118.2x · P/E ex non-operating (est.) ≈26.1x · P/S 3.0x · EV/EBITDA 14.7x · EV/Sales 3.0x · P/FCF 22.1x · P/B 3.0x · FCF yield 4.53% · Earnings yield 0.85% · Net cash $557K · EV $92.5M
Insider purchases (SEC Form 4, open-market, last ~7 months) (ICCC)
1 purchase, $76K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-06-18 | Te Boekhorst Paul Francis Olivier | President and CEO | 8,000 | $76K | 9.49 | Too little history (no open-market trades in 2023 or 2024) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (ICCC)
Consensus None.
Total return (dividends reinvested) (ICCC)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +71.7% | +16.5% |
| S&P 500 (SPY) | +14.0% | +76.9% |
| Per year | +72.3% | +3.1% |
| Volatility (annualized) | 50.5% | 43.7% |
| Max drawdown | -27.7% (Nov 2025→Nov 2025) | -64.8% (Mar 2022→Nov 2024) |
ICCC revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Corporate Segment Scours | $7.1M | 99.0% | +11.1% |
| Corporate Segment Mastitis | $75,344 | 1.0% | +62.5% |
| Total revenue | $7.2M | 100% | — |
ICCC revenue by product line (quarter ended Jun 30, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| First Defense Product Line | $6.4M | 99.3% | +17.8% |
| Other Animal Health | $46,363 | 0.7% | +8.3% |
| Total revenue | $6.4M | 100% | — |
ICCC revenue by region (quarter ended Jun 30, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $4.9M | 75.6% | -0.4% |
| Other States | $1.6M | 24.4% | +170.4% |
| Total revenue | $6.4M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
ICCC suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Craig-Hallum Capital Group | “Our sources of liquidity and capital resources are cash flows from operations, proceeds from our sale of common stock under our At-The-Market Agreement with Craig-Hallum Capital Group LLC (ATM Agreement), and borrowings available under our bank line of credit.” |
| Competitor | Merck (MRK) | “Our competitors in U.S. and international scours prevention markets are some of the largest animal health companies worldwide, including Zoetis, Elanco, Merck, Boehringer Ingelheim and CEVA, among others.” |
Quoted from the company's 10-K filed Mar 30, 2026.
ICCC customer concentration
In the period ended Jun 30, 2026, 3 direct customers each accounted for at least 10% (73%, 51%, 22%) of revenue, per the company's 10-Q filed Aug 13, 2026. The company does not name them.
ICCC company outlook (results filed Oct 13, 2026)
- “Such statements involve risks and uncertainties and are based on our current expectations, but actual results may differ materially due to various factors, including the risk factors summarized under PART II: OTHER INFORMATION, ITEM 1A-RISK FACTORS and uncertainties otherwise referred to in the Annual Report.”
Quoted word-for-word from the SEC 8-K results press release.
ICCC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Mar 2021) | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2021) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 01:11 UTC)
| Price | USD 10.25 |
|---|---|
| Change | ▼ 1.35% (down) |
| Previous Close | USD 10.39 |
| Open | USD 10.36 |
| Day Range | USD 10.2 – 10.37 |
| 52-Week Range | USD 4.52 – 12.1 |
| Volume | 11,223 shares |
| Market Cap | $93.09M |
| Exchange | NCM |
Technical Analysis (ICCC)
Nexqual's technical model rates ICCC "STRONG BUY" based on 5 bullish and 0 bearish signals across 126 daily candles, as of October 24, 2026 at 01:11 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.57 (neutral) |
| vs SMA50 | Above (USD 10.01) |
| MACD | 0.16 (positive) |
Analyst Ratings (ICCC)
Wall Street analysts rate ICCC "None", per Nexqual as of October 24, 2026 at 01:11 UTC.
| Consensus Rating | None |
|---|
Earnings (ICCC)
| Next Earnings Date | 2026-11-12 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2020-12-31 | USD 0.03 vs est -0.04 ▲ beat |
| 2020-09-30 | USD -0.04 vs est -0.08 ▲ beat |
| 2020-06-30 | USD -0.11 vs est -0.1 ▼ miss |
Source: Nexqual, October 24, 2026 at 01:11 UTC.
Financials & Fundamentals (ICCC)
| Total Revenue | $30.68M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +11.50% |
| Gross Margin | +40.32% |
| Operating Margin | +26.93% |
| Profit Margin | +2.57% |
| ROE | +2.57% |
| Debt / Equity | 0.4 |
| Current Ratio | 4.75 |
| Total Cash | $8.86M |
| Total Debt | $12.45M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $4.21M (13.7% of revenue) |
Source: Nexqual, October 24, 2026 at 01:11 UTC.
Financial Health Score (ICCC)
Nexqual rates ImmuCell Corporation's overall financial health "Mixed" across five dimensions, as of October 24, 2026 at 01:11 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $9M cash and investments vs $8M debt (Jun 2026, SEC), net cash |
| Cash Flow | Solid — FCF $4M (last 4 quarters to Jun 2026, SEC), 14% margin |
| Efficiency | Weak — ROE 3%, ROA 6.2% |
Ownership (ICCC)
| Insider Ownership | +32.09% |
|---|---|
| Institutional Ownership | +20.32% |
| Shares Outstanding | 9.08M |
| Float | 6.03M |
| Short % of Float | +0.29% |
Source: Nexqual, October 24, 2026 at 01:11 UTC.
Leadership (ICCC)
ImmuCell Corporation is led by Paul F. Olivier Te Boekhorst, President, CEO & Director, per Nexqual as of October 24, 2026 at 01:11 UTC.
| President, CEO & Director | Paul F. Olivier Te Boekhorst |
|---|---|
| CFO, Secretary & Treasurer | Timothy C. Fiori |
| Senior Vice President of Sales & Marketing | Bobbi Jo Brockmann |
| Director of Finance & Administration and Controller | Elizabeth S. Toothaker |
| Senior Director of Quality | A. Gustavo Scaffa |
Major Backers & Investors (ICCC)
Notable institutional backers of ImmuCell Corporation include Morgan Stanley, Renaissance Technologies, Cresset Asset Management, LLC, according to Nexqual as of October 24, 2026 at 01:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 2.58% |
| Renaissance Technologies | 1.88% |
| Cresset Asset Management, LLC | 1.49% |
| Fidelity | 0.62% |
| Bleichroeder LP | 0.55% |
| Steadtrust LLC | 0.5% |
| Mesirow Financial Investment Management, Inc. | 0.47% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.95% |
| Geode Capital | 0.8% |
| Dimensional Fund Advisors | 0.64% |
Source: Nexqual, October 24, 2026 at 01:11 UTC.
From ImmuCell Corporation's Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Based on market data we acquire from a market leading animal health data provider, spend on biological scours preventative was more than $90 million in 2025, an increase of approximately 14% from 2024, representing a cumulative average growth rate of 6.9% since 2021.
- Approximately $2.9 million of this investment was offset by related product licensing revenues and grant income, most of which was earned from 2001 to 2007.
- Approval by the FDA of a New Animal Drug Application (NADA) for Re-Tain® is required before any sales of the product can be initiated.
- In December 2025, we announced our strategy to focus on First Defense® and paused further investment in manufacturing Re-Tain®, to allow us to focus on the scours market opportunity.
Partnerships
- Products are marketed through the Company's commercial sales organization in collaboration with a network of international, national and regional animal health distributors.
Legal & Regulatory Risks (Item 1A, quoted)
- Economic Risks Pertaining to the Dairy and Beef Industries
- Small Size of the Company
- Risks Pertaining to Common Stock
- The existence of the foregoing provisions and anti-takeover measures could adversely affect the trading price of our common stock or limit the price that investors might be willing to pay in the future for shares of our common stock.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 303.53 | ▼ 1.39% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.27 | ▼ 1.79% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.09 | ▼ 0.35% |
| PRAX | Praxis Precision Medicines, Inc | USD 252.96 | ▼ 2.3% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.93 | ▼ 2.23% |
| AXSM | Axsome Therapeutics, Inc. | USD 145.04 | ▼ 7.07% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 01:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt